top of page
Search

Motif Neurotech raises $18.75 million to advance an implantable device for treatment-resistant depression

Funding to advance development of miniature implantable stimulator to unlock minimally invasive therapies for treatment-resistant neuropsychiatric disorders




Motif Neurotech, a neurotechnology company developing minimally-invasive bioelectronics for mental health, announced today an oversubscribed Series A financing of $18.75 million led by Arboretum Ventures, with participation from new investors KdT Ventures, Satori Neuro, Dolby Family Ventures, re.Mind Capital, individual investor Max Hodak and existing investors Divergent Capital, TMC Innovation, PsyMed Ventures, Empath Ventures and Capital Factory.

“Minimally-invasive bioelectronics are the future of mental health treatment” Post this

Proceeds from the Series A financing will be used to advance the development of Motif’s lead product, DOT microstimulator, a miniature brain pacemaker designed to precisely stimulate the brain to restore healthy circuit activity to treat mental health disorders. The initial indication Motif is pursuing for the device is treatment-resistant depression (TRD), a form of major depressive disorder (MDD) that is resistant to anti-depressant medications.


“Minimally-invasive bioelectronics are the future of mental health treatment,” said Jacob Robinson, CEO & Founder, Motif Neurotech. “30% of patients with depression don’t respond to two or more medications, and there is a significant need for additional treatment options that are effective and easily accessible. The DOT microstimulator is a wireless, battery-free device designed to be implanted in a 20-minute outpatient procedure with the capability for at-home therapy. This round of financing will allow us to bring this technology into a clinical study for patients with TRD.”


“We believe Motif’s device will greatly improve the quality of life for patients who have been diagnosed with difficult to treat mental health disorders, including TRD,” said Tom Shehab, managing partner of Arboretum Ventures. “We are proud to lead this round of financing with this world-class team.”


Amy Kruse, chief investment officer of Satori Neuro and Tom Shehab will join the Board of Directors at Motif Neurotech, alongside Anthony Arnold, and Jacob Robinson.


About Motif Neurotech

Motif Neurotech is pioneering wireless minimally-invasive neuromodulation therapeutics for mental health. The company’s lead product is a miniature implant in development for treatment resistant depression. Motif’s implant is enabled by wireless magnetoelectric power transfer technology developed at Rice University and founded by Rice Faculty Jacob Robinson, Kaiyuan Yang, and physicians Sunil Sheth, and Sameer Sheth.


For more information visit www.motifneuro.tech. Follow us on LinkedIn and Twitter @motifneuro.


Source: Motif Neurotech


_____________________________________________________

What are your company's business or financial objectives?







If your company has business or financial objectives, check out the advisory services for growing life sciences companies provided by FC Global Strategies.


Our calendar link to schedule a complementary call.


FC Global Strategies' Regional Directors:


Jeffrey Friedland - Based in the U.S.

(North America and Global)

+1 646 450 8909


Ross Swan - Based in Singapore

(Southeast Asia, Australia, Asia-Pacific)

+65 9181 9472


David Krutonog - Based in Israel

(Eastern Europe, Middle-East and North Africa

+972 50 974 3429


Claudio Hebling - Based in Brazil

(Latin America)

+55 19 99377 748


Vincent Paul Joseph - Based in India

(South Asia, India and Sri Lanka)

+91 962 620 9090


Olah Abiodun - Based in Nigeria

(Sub-Saharan Africa)

+234 812 029 8222







bottom of page